Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus

NCT05232071 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

NASH - Nonalcoholic Steatohepatitis
Diabetes Mellitus, Type 2

Interventions

DRUG: IVA337
DRUG: Placebo
DRUG: Empagliflozin

Sponsor

Inventiva Pharma